-
601
A Tumor Suppressive Role of CYLD as a Novel Potential DUB of Aurora B in Cervical Cancer
Published 2023-06-01Get full text
Article -
602
-
603
Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
Published 2021-07-01Get full text
Article -
604
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RA...
Published 2024-01-01“…The type II RAF inhibitor, tovorafenib (formerly DAY101, TAK-580, MLN2480), has shown promising activity and good tolerability in patients with BRAF-altered pLGG in the phase 2 FIREFLY-1 study, with an objective response rate (ORR) per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria of 67%. …”
Get full text
Article -
605
Negative regulation of miR‐1275 by H3K27me3 is critical for glial induction of glioblastoma cells
Published 2019-07-01Get full text
Article -
606
Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study
Published 2021-04-01Get full text
Article -
607
The design and evaluation of hybrid controlled trials that leverage external data and randomization
Published 2022-10-01Get full text
Article -
608
Reverse Takotsubo cardiomyopathy after orthotopic liver transplantation. A case report
Published 2022-05-01Get full text
Article -
609
Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches
Published 2023-12-01Get full text
Article -
610
-
611
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Published 2023-01-01“…Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing great interest in the neuro-oncology community. While several reports show that subsets of patients with glioma exhibit durable responses to immunotherapy, the efficacy of this treatment has not been observed for unselected patient populations, preventing its broad clinical implementation for gliomas and glioblastoma (GBM). …”
Get full text
Article -
612
Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals
Published 2021-07-01Get full text
Article -
613
ZEB1 Is a Transcription Factor That Is Prognostic and Predictive in Diffuse Gliomas
Published 2019-01-01Get full text
Article -
614
-
615
The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression
Published 2022-03-01“…Among the adult-type diffuse gliomas, glioblastoma represents most primary brain tumors in the neuro-oncology practice of adults. Despite massive efforts in the field of neuro-oncology diagnostics to ensure a proper taxonomy, the identification of glioblastoma-tumor subtypes is not accompanied by personalized therapies, and no improvements in terms of overall survival have been achieved so far, confirming the existence of open and unresolved issues. …”
Get full text
Article -
616
-
617
-
618
-
619
-
620